Want to see BRTX full AI Analyst Report?
BRTX Stock Chart & Stats
$0.22
-$0.01(-4.48%)
At close: 4:00 PM EDT
$0.22
-$0.01(-4.48%)
Day’s Range― - ―
52-Week Range$2.26 - $34.60
Previous Close$0.29
Volume676.57K
Average Volume (3M)27.73K
Market Cap
$3.22M
Enterprise Value$1.27
Total Cash (Recent Filing)$3.59M
Total Debt (Recent Filing)$34.52K
Price to Earnings (P/E)―
Beta1.01
Next Earnings
Nov 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-22.20
Shares Outstanding1,381,128
10 Day Avg. Volume34,343
30 Day Avg. Volume27,730
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)29.75
Price to Sales (P/S)29.50
P/FCF Ratio-0.97
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-6.6
Revenue Forecast (FY)$2.50M
Bulls Say, Bears Say
Bulls Say
Minimal LeverageEffectively no debt limits interest obligations and reduces the risk that lenders constrain operations. This gives BioRestorative greater flexibility to direct available capital toward research and clinical programs, although it does not eliminate the need for future funding.
Positive Gross MarginA 63% gross margin indicates that the company’s reported activities can generate meaningful gross profit before operating expenses. If revenue grows, this contribution could help absorb fixed costs, though current losses show that scale has not yet been achieved.
Regenerative Medicine PipelinePrograms addressing chronic lumbar disc disease and metabolic disorders give the company exposure to substantial healthcare needs and create potential long-term value from its cell-based platform. The opportunity remains contingent on successful development and regulatory progress.
Bears Say
Very Weak Revenue And ProfitabilityThe small and declining revenue base is far from sufficient to support the current cost structure, while the deeply negative net margin shows that operations remain substantially unprofitable. Without stronger commercialization or milestone income, earnings durability remains weak.
Persistent Cash BurnSustained operating and free-cash-flow deficits indicate that the business consumes substantial capital relative to its revenue. Continued research and operations therefore rely on external funding, which can constrain strategic flexibility and create ongoing financing pressure.
Executive Governance InstabilityA disputed senior executive departure, contested employment terms, and a special-counsel investigation create governance distraction during a critical development period. Uncertainty around leadership obligations may complicate execution, oversight, and capital allocation over the next several quarters.
BioRestorative Therapies News
BRTX FAQ
What was BioRestorative Therapies’s price range in the past 12 months?
BioRestorative Therapies lowest stock price was $2.26 and its highest was $34.60 in the past 12 months.
What is BioRestorative Therapies’s market cap?
BioRestorative Therapies’s market cap is $3.22M.
When is BioRestorative Therapies’s upcoming earnings report date?
BioRestorative Therapies’s upcoming earnings report date is Nov 18, 2026 which is in 47 days.
How were BioRestorative Therapies’s earnings last quarter?
BioRestorative Therapies released its earnings results on May 20, 2026. The company reported -$0.2 earnings per share for the quarter.
Is BioRestorative Therapies overvalued?
According to Wall Street analysts BioRestorative Therapies’s price is currently Overvalued.
Does BioRestorative Therapies pay dividends?
BioRestorative Therapies does not currently pay dividends.
What is BioRestorative Therapies’s EPS estimate?
BioRestorative Therapies’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioRestorative Therapies have?
BioRestorative Therapies has 1,381,128 shares outstanding.
What happened to BioRestorative Therapies’s price movement after its last earnings report?
BioRestorative Therapies reported an EPS of -$0.2 in its last earnings report. Following the earnings report the stock price went down -3.182%.
Which hedge fund is a major shareholder of BioRestorative Therapies?
Currently, no hedge funds are holding shares in BRTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioRestorative Therapies
BioRestorative Therapies, Inc. is a life sciences company dedicated to developing regenerative medicine products and therapies. Their approach primarily utilizes adult stem cell protocols to address two key areas: disc/spine disease and metabolic disorders. Within their disc/spine program, known as brtxDisc, the company's leading cell therapy candidate is BRTX-100. This treatment involves culturing mesenchymal stem cells harvested from a patient's own bone marrow (autologous) to provide a non-surgical solution for painful lumbosacral disc conditions. BRTX-100 has successfully completed Phase 1 clinical trials. The company is also advancing its Metabolic Program, named ThermoStem, which is currently in the preclinical stage. This cell-based therapy targets obesity and other metabolic ailments by employing brown adipose-derived stem cells to generate brown adipose tissue. Beyond these core programs, BioRestorative Therapies also offers an investigational curved needle device designed for delivering cells and various therapeutic materials to the spine and discs. The company fosters strategic research and development partnerships, including agreements with Rohto Pharmaceutical Co., Ltd., Pfizer, Inc., and the University of Pennsylvania. Founded in 1997 and headquartered in Melville, New York, the company was initially known as Stem Cell Assurance, Inc., before rebranding to BioRestorative Therapies, Inc. in August 2011.
Technical Analysis
Ownership Overview
26.86% Insiders
4.01% Mutual Funds
― Other Institutional Investors
66.34% Public Companies and
Individual Investors